| Website | allozyne.com |
| Category | BioTech |
| Phone | 206-518-5700 |
| info@allozyne.com | |
| Employees | |
| Founded | 2005 |
| TOTAL | $33.5M |
| FUNDING TOTAL | $33.5M |
| Series A, 12/05 MPM Capital ARCH Venture Partners OVP Venture Partners Amgen Ventures | $3.5M |
| Series B, 10/07 MPM Capital OVP Venture Partners Amgen Ventures ARCH Venture Partners Alexandria Real Estate Equities | $30M |
Allozyne develops and commercializes technologies that enable improvements in the efficacy, safety, dosing, and other characteristics of protein-based therapeutics, including peptides, antibodies, and vaccines. Its PEGylated IFN beta is for the treatment of multiple sclerosis. The company was founded in 2005 and is based in Seattle, Washington.
